Please login to the form below

Not currently logged in
Email:
Password:

Lilly elects Prof Carolyn Bertozzi to board of directors

She brings oncology, inflammation and infection research expertise to the firm

Eli Lilly has elected Prof Carolyn Bertozzi to its board of directors, where she will serve as a member of the science and technology, public policy and compliance committees.

Prof Bertozzi is currently the Anne T and Robert M Bass professor of chemistry and professor of chemistry and systems biology and radiology at Standford University, and serves as an investigator at the Howard Hughes Medical Institute.

She first joined Stanford in 2015 with the launch of its ChEM-H Institute, having previously been a member of the UC Berkley College of Chemistry.

Her research focuses on profiling changes in cell surface glycosylation associated with cancer, inflammation and bacterial infection to develop diagnostic and therapeutic approaches.

Prof Bertozzi is a member of the Institute of Medicine, National Academy of Sciences, and American Academy of Arts and Sciences.

Dr John Lechleiter, chairman of Eli Lilly's board of directors, said: “We are very pleased to welcome Carolyn Bertozzi to the Lilly board.

“Professor Bertozzi, with her broad scientific expertise and solid record of accomplishment, along with her understanding of the biopharmaceutical industry, will contribute greatly to our board and our company as we seek to advance Lilly's pipeline of potential new medicines to benefit patients and our other key stakeholders.”

17th February 2017

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Enabling market access through outcomes-based pricing
Outcomes-based pricing is a potential solution to create a link between product price and real-world outcomes, while at the same time facilitating patient access to new and innovative medicines....
Five companies 20 for 2020
20 for 2020 – Five pharma companies to watch
As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
The growing clinical importance of patient-reported outcomes (PROs)
Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...

Infographics